NCT06059690 Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
| NCT ID | NCT06059690 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Jonsson Comprehensive Cancer Center |
| Condition | Glioblastoma Multiforme |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-09-06 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 50 participants in total. It began in 2023-09-06 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Investigators will then correlate the imaging measurements with pH, RNA expression, protein expression, and bioenergetics measurements of key glycolytic enzymes.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 * Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery Exclusion Criteria: * Patients who cannot obtain an MRI or FDG PET scan with contrast * Those with ferromagnetic implanted devices that might produce a safety hazard (e.g. infusion pumps, pace makers, aneurysm clips, etc.) will be excluded from the study along with subjects with severe claustrophobia or who have severely compromised renal function (GFR \< 30).
Contact & Investigator
Benjamin Ellingson, PhD
PRINCIPAL INVESTIGATOR
University of California at Los Angeles
Frequently Asked Questions
Who can join the NCT06059690 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioblastoma Multiforme. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06059690 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06059690 currently recruiting?
Yes, NCT06059690 is actively recruiting participants. Contact the research team at RNagaraj@mednet.ucla.edu for enrollment information.
Where is the NCT06059690 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06059690 clinical trial?
NCT06059690 is sponsored by Jonsson Comprehensive Cancer Center. The principal investigator is Benjamin Ellingson, PhD at University of California at Los Angeles. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.